Postmenopausal women taking anastrozole as a chemopreventive treatment do not have impaired cognitive performance
User rating: 5 / 5 after 1 vote(s)
New results of a sub-study carried out as part of a worldwide breast cancer prevention study (IBIS-II) show that after two years of taking the aromatase inhibitor, anastrozole, postmenopausal women at high risk of breast cancer do not have impaired cognitive performance.
Full story »
|

PhysOrg Forum
Video
Editorials
Free Magazines
Newsletter
Goto Archive
Suggest a story idea
Send feedback